FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results

If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposureInterim analysis results from first-of-its-kind phase III OUtMATCH study...

Related Keywords

Switzerland ,Japan ,United States ,America ,Bruno Eschli ,Simon Goldsborough ,Kirti Pandey ,Sileia Urech ,Birgit Masjost ,Karsten Kleine ,Sabine Borngr ,Nathalie Altermatt ,Levi Garraway ,Rebekka Schnell ,Loren Kalm ,Genentech ,Drug Administration ,National Institute Of Allergy ,National Institutes Of Health ,Consortium Of Food Allergy Research Co ,Novartis Pharmaceuticals Corporation ,Genentech Inc ,Public Health Impact Of Parent ,Head Of Global Product Development ,Inspection Service ,Roche Group ,Priority Review ,Biologics License Application ,National Institutes ,Chief Medical Officer ,Global Product ,Safety Monitoring Board ,National Institute ,Infectious Diseases ,Food Allergy Research ,Novartis Pharmaceuticals ,Breakthrough Therapy Designation ,Therapy Designation ,Adjunct Therapy ,Food Allergic Children ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Food Allergies Among ,Curr Allergy Asthma ,Public Health Impact ,Parent Reported Childhood Food Allergies ,Food Allergic Participants ,Markets ,